Disease modifying antirheumatic drug market

Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI5185
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Disease-modifying antirheumatic drugs (DMARDs) are a group of medications commonly used in people with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. Disease-modifying antirheumatic drugs work to decrease pain and inflammation, to reduce or prevent joint damage, and to preserve the structure and function of the joints.

The global disease-modifying antirheumatic drug (DMARD) market is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% during the forecast period (2022-2030).

Figure 1.Global Disease-Modifying Antirheumatic Drug (DMARD) Market Share (%) in Terms of Value, By Drug Type, 2022

Increasing prevalence of rheumatoid arthritis disease is expected to drive the market growth during the forecast period.

Increasing prevalence of rheumatoid arthritis disease which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth over the forecast period. For instance, according to data published by National Center for Biotechnology Information in June 2022, stated that the annual incidence of RA (Rheumatoid Arthritis) in the U.S. and other western nations of northern Europe is about 40 per 100,000 persons.

Disease-Modifying Antirheumatic Drug (DMARD) Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 20,671.1 Mn
Historical Data for:	2017-2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	3.5%	2030 Value Projection:	US$ 27,167.8 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Type: Synthetic (sDMARD) (Conventional synthetic (csDMARDs) (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine, Gold Salts)), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD) ( Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs) (Primary, Secondary, Tertiary))), Others By Route of Administration: Oral, Parenteral, Others By Indication: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Others By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:	Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc
Growth Drivers:	Increasing prevalence of rheumatoid arthritis disease Increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc.
Restraints & Challenges:	Side effects associated with the disease-modifying antirheumatic drug

Figure 2. Global Disease-Modifying Antirheumatic Drug (DMARD) Market Share (%), By Distribution Channel, 2022

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc., are expected to drive the market growth during the forecast period

Increasing product launches for the treatment of rheumatoid arthritis, psoriasis which is expected to drive the global disease-modifying antirheumatic drug (DMARD) market growth during the forecast period. For instance, in November 2020, Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announced the launch of RediTrex injection. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis.

Global Disease-Modifying Antirheumatic Drug (DMARD) Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global intraocular melanoma treatment market. Thus, COVID-19 pandemic is expected to have negative impact on supply chain of disease-modifying antirheumatic drug market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Disease-Modifying Antirheumatic Drug (DMARD) Market: Restraint

The major factors that hinder growth of the global disease-modifying antirheumatic drug (DMARD) market include side effects associated with the disease-modifying antirheumatic drug. Azathioprine (Imuran) is used for many different inflammatory conditions, including RA. The most common side effects are nausea and vomiting, sometimes with stomach pain and diarrhea. Long-term use of azathioprine is associated with an increased risk of cancer.

Key Players

Key players operating in the market include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Disease-Modifying Antirheumatic Drug (DMARD) Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the Global Disease-Modifying Antirheumatic Drug (DMARD) Market during the forecast period (2022-2030)?

The Global Disease-Modifying Antirheumatic Drug (DMARD) Market size is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% between 2022 and 2030

What are the major factors driving the market growth?

Factors such as increasing prevalence of rheumatoid arthritis disease and increasing product launches for the treatment of rheumatoid arthritis, psoriasis, etc., are expected to drive the market growth over forecast period

Which is the leading drug type segment in the market?

Synthetic (sDMARD) segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include high side effects associated with the medication

Which are the major players operating in the market?

Major players operating in the market are Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.